Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

NeuroPace (NPCE) EBIAT (2020 - 2026)

NeuroPace has reported EBIAT over the past 7 years, most recently at -$6.7 million for Q1 2026.

  • For Q1 2026, EBIAT fell 1.52% year-over-year to -$6.7 million; the TTM value through Mar 2026 reached -$21.6 million, up 13.06%, while the annual FY2025 figure was -$21.5 million, 20.91% up from the prior year.
  • EBIAT for Q1 2026 was -$6.7 million at NeuroPace, down from -$2.7 million in the prior quarter.
  • Over five years, EBIAT peaked at -$2.7 million in Q4 2025 and troughed at -$12.7 million in Q2 2022.
  • A 5-year average of -$8.0 million and a median of -$7.5 million in 2024 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: plummeted 49.4% in 2022 and later skyrocketed 48.02% in 2025.
  • Year by year, EBIAT stood at -$11.1 million in 2022, then soared by 44.37% to -$6.2 million in 2023, then rose by 15.32% to -$5.2 million in 2024, then skyrocketed by 48.02% to -$2.7 million in 2025, then plummeted by 145.11% to -$6.7 million in 2026.
  • Business Quant data shows EBIAT for NPCE at -$6.7 million in Q1 2026, -$2.7 million in Q4 2025, and -$3.5 million in Q3 2025.